Literature DB >> 28249076

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Gerard Sanacora1, Mark A Frye2, William McDonald3, Sanjay J Mathew4, Mason S Turner5, Alan F Schatzberg6, Paul Summergrad7, Charles B Nemeroff8.   

Abstract

IMPORTANCE: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. OBSERVATIONS: This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option. CONCLUSIONS AND RELEVANCE: The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28249076     DOI: 10.1001/jamapsychiatry.2017.0080

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  102 in total

1.  Direct administration of ifenprodil and citalopram into the nucleus accumbens inhibits cue-induced nicotine seeking and associated glutamatergic plasticity.

Authors:  Jonna M Leyrer-Jackson; Jose A Piña; Joseph McCallum; M Foster Olive; Cassandra D Gipson
Journal:  Brain Struct Funct       Date:  2020-06-26       Impact factor: 3.270

Review 2.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

3.  Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.

Authors:  Gihyun Yoon; Ismene L Petrakis; John H Krystal
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

Review 4.  Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.

Authors:  Jason Ng; Leanna M W Lui; Joshua D Rosenblat; Kayla M Teopiz; Orly Lipsitz; Danielle S Cha; Jiaqi Xiong; Flora Nasri; Yena Lee; Kevin Kratiuk; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Roger Ho; Bing Cao; Roger S McIntyre
Journal:  Psychopharmacology (Berl)       Date:  2021-01-23       Impact factor: 4.530

5.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

6.  Promoting the Discussion of the Beneficial Effects of Ketamine to Treat Refractory Depression.

Authors:  Priyanka Ghosh; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2019-02-15

7.  Influence of anesthetic induction of propofol combined with esketamine on perioperative stress and inflammatory responses and postoperative cognition of elderly surgical patients.

Authors:  Wencai Tu; Haibo Yuan; Shaojin Zhang; Fang Lu; Lin Yin; Chuanfeng Chen; Jianhua Li
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

8.  Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.

Authors:  Katrin Weigmann
Journal:  EMBO Rep       Date:  2018-10-15       Impact factor: 8.807

9.  Sex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability.

Authors:  Katherine N Wright; Mohamed Kabbaj
Journal:  Curr Opin Behav Sci       Date:  2018-03-02

10.  Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Authors:  Marlene P Freeman; George I Papakostas; Bettina Hoeppner; Erica Mazzone; Heidi Judge; Cristina Cusin; Sanjay Mathew; Gerard Sanacora; Dan Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Psychiatr Res       Date:  2019-01-08       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.